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Abstract
Despite the advances in renal transplantation over the last decades, chronic allograft dysfunction remains the largest concern for
patients, their families, clinicians and other members of the multi-disciplinary team. Although we have made progress in
improving patient and renal allograft survival within the first year after transplantation, the rate of transplant failure with
requirement for commencement of dialysis or re-transplantation has essentially remained unchanged. It is important that paedi-
atric and adult nephrologists and transplant surgeons, not only manage their patients and their renal transplants but provide the
best chronic kidney disease management during the time of decline of renal allograft function. The gold standard for patients with
Stage V chronic kidney disease is to have pre-emptive living donor transplants, where possible and the same is true for healthy
renal transplant recipients with declining renal allograft function. The consideration for children and young people as they
embark on their end-stage kidney disease journey is the risk-benefit profile of giving the best immunologically matched and
good quality renal allografts as they may require multiple renal transplantation operations during their lifetime.
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Introduction
Transplant professionals often exhort their colleagues to con-
sider pre-emptive renal transplantation as the primary form of
renal replacement therapy, preferably with a living donor. It
would seem intuitive that the same individuals would be in-
strumental in ensuring pre-emptive second and subsequent
transplants for their patients. However, there is evidence that
this is not the case and that more effort could be made to
ensure a smooth transition to a pre-emptive second and sub-
sequent transplant for those who are fit enough to receive one.
While there are good data on renal allograft failure rates in
the U K through the adult and paediatric kidney specific
report, published annually by NHS Blood and Transplant
(NHSBT), there is a paucity of data on re-transplantation rates
since they are not included in the UK Renal Registry (UKRR)
annual report. The kidney specific report indicates that for
adults in the UK, death censored renal allograft loss at 5 years
is 13% for deceased donor renal transplant recipients (RTRs)
and 7% for live donors, compared to 17 and 14% respectively
in children [1]. In the USA, 13.1% of the adult waiting list was
for re-transplantation in 2015, compared to 16.1% in 2005,
compared to 16.9 and 24.6% respectively for the paediatric
waiting list [2]. The actual re-transplantation rates performed
were 13.2% (n = 2354) in adults and 8.5% in children (n =
186). The consideration for children and young people as they
embark on their end-stage kidney disease journey is the risk-
benefit profile of giving the best immunologically matched
and good quality renal allografts as they may require multiple
renal transplantation operations during their lifetime. This was
emphasised by a Dutch study of 249 RTRs, all transplanted
under the age of 15 years, which showed that after a mean
follow-up of 25 years of follow-up, 36, 34, 17 and 5% had
been transplanted two, three, four and five or more times,
respectively [3]. Consequently, it is important to ensure that
the pathway is as smooth as possible and to minimise the time
spent on dialysis.
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Adult RTRs with an estimated glomerular filtration rate
(eGFR) less than 30 mls/min/1.73m2 contributed 13.3% of the
UK transplant population in 2015 according to the 19th UKRR
report [4]. This represents nearly 4500 patients with stages IV-T
and V-T chronic kidney disease. Evidence from the UK Renal
Registry demonstrates that the care of these patients is subopti-
mal. For example, across the UK, 16% of these patients have a
haemoglobin less than 100 g/L, and less than a quarter achieved
satisfactory blood pressure control (< 130/80 mmHg).
There was a high incidence of chronic kidney disease com-
plications in our published cohort of 129 paediatric RTRs of
whom 66% had stages III-T or IV-T chronic kidney disease
[5]. There was evidence of treatment for hypertension in 53%
(of whom 7% had uncontrolled hypertension), albuminuria in
60%, anaemia in 50%, acidosis in 39%, hyperparathyroidism
in 20%, hypoalbuminaemia in 16%, hyperphosphataemia in
12% and hypocalcaemia in 3%. Interestingly, 30% of RTR
were pre-emptively transplanted with their first transplant,
and they had improved outcomes and reduced incidence of
stage IV-T chronic kidney disease [6].
Data (extracted in October 2017 for 1007 adult RTRs) from
our adult unit revealed 73 patients with an eGFR ≤ 20 mls/min/
1.73m2. In this group, 19.2% had a bicarbonate under 20 mmol/
L, 39.7% had a haemoglobin less than 100 g/l, 30.1% had a
PTH greater than 30 pmol/l and only 30% (22/73) had been
assessed for re-transplantation. Data from the USA described
nearly two thirds of failing adult transplant patients commencing
haemodialysis with intravenous catheters which is disappointing
since they are nearly all under regular renal review [7]. These
issues with patient care will be exacerbated by the continuing
expansion of this population group which will make manage-
ment increasingly difficult unless resources are allocated accord-
ingly. As a result of the successful increase in deceased donor
renal transplantation rates in the UK, the prevalent adult trans-
plant population has increased from 19,074 in 2005 to 32,624 in
2015. To meet this challenge, some units have established trans-
plant low clearance clinics to facilitate bettermanagement of this
patient population. The recent UK Renal Registry report mea-
sured the evolution of renal function after transplantation with
the median change in eGFR being − 0.56mls/min/1.73m2/year
in adults. Interestingly, significantly faster rates of deterioration
were described in RTRs who were younger, non-white, female
or diabetic. These interesting findings warrant further investiga-
tion and may identify high risk sub groups. Renal transplant
recipients whose transplant failed during the time period (n =
1306) had a median decline rate of − 6.3mls/min/1.73m2/year
(IQR − 3.0 to − 12.1) which can be used to guide the process of
working these patients up for further renal replacement therapy.
Outcomes after the failure of a transplant are generally
poor. A meta-analysis of 40 studies in adults revealed that
the mortality rate in the first 12 months following renal allo-
graft failure was approximately 12% for the first 12 months
dropping to around 6% for the next 3 years [8]. This is
equivalent to the mortality rate a 70-year old first time starter
on dialysis therapy in the UK. Even among the cohort who are
fit enough relisted outcomes are inferior compared with trans-
plant naïve patients, a recent study from Spain demonstrating
a 50% increase in mortality [9]. A study derived from the
Dialysis Outcomes and Practice Patterns Study (DOPPS)
compared the outcomes in adult patients starting dialysis ei-
ther for the first time (n = 2806) or after transplant failure (n =
1865) [10]. The patients with failing transplants had signifi-
cantly higher mortality and hospitalisation rates, particularly
related to infection. In addition, they had significantly lower
quality of life scores and a significantly higher prevalence of
depression. The psychological effects of renal allograft failure
cannot be overstated, and detailed psychological studies have
described the devastating effects of renal allograft failure, lik-
ening the process to a disenfranchised grief reaction (i.e.
where the griever is not recognised as an individual who can
and should grieve) [11]. Despite these observations, there is
still data to suggest benefit of a second pre-emptive transplant
with improved patient and graft outcomes [12, 13].
There is published guidance in the British Transplantation
Society Guidelines for the Management of the Failing Kidney
Transplant [14] and also the Renal Association Guidelines for
the Planning, Initiating andWithdrawal of Renal Replacement
Therapy [15]. These documents contain many sensible recom-
mendations although it is conspicuous that the evidence levels
are low. Implementation of these standards in the burgeoning
renal transplant population is likely to present a considerable
challenge. Realisation of guideline standards has unfortunate-
ly received far less attention than the diligent work that has
gone into formulating them, and registry data reflects the fact
that quite simple targets are frequently not achieved.
There is little evidence to guide the timing of dialysis initiation
after renal transplantation. Seminal studies in patients with native
renal failure have suggested that early initiation is not beneficial
[16]. Limited data in RTR with failing grafts have revealed an
association between higher eGFR at initiation and worse out-
comes [17, 18]. It seems sensible that renal replacement therapy
should be commenced for symptoms or fluid control.
Indications for graft nephrectomy are well established but it
should be appreciated that there is a mortality rate of up to 1.5%
at 30 days [19, 20]. There is evidence that graft nephrectomy is
associated with a risk of sensitisation to both Human Leukocyte
Antigens (HLA) classes I and II [21]. However, interpretation
of this data is confounded by another of other factors:
& The indication for nephrectomy is often the result of a
clinical syndrome caused by antibody-mediated rejection
& Peri-operative transfusion may occur
& Intracapsular nephrectomy leaves increased allogeneic
material compared to extracapsular extraction
& Variation in immunosuppression withdrawal protocols
around the time of nephrectomy
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& Loss of the Bsponge^ effect as the graft no longer Bmops
up^ antibodies
We have shown that 53% of paediatric RTR with renal
allograft failure underwent transplant nephrectomy over a de-
cade in our unit [22]. Grade II Banff rejection, an inflamma-
tory response and early graft loss within the first year after
renal transplantation are more likely to require transplant ne-
phrectomy, which may be associated with higher circulating
HLA antibody levels in paediatric RTR.
A randomised controlled trial of nephrectomy in asymp-
tomatic patients is required to resolve this issue and to decide
whether it is the nephrectomy per se, or the inflammatory
milieu that leads to nephrectomy, which triggers sensitisation.
The correct strategy for weaning immunosuppression (IS)
is not clear and there are conflicting priorities as shown in
Table 1. Interpreting the outcome of IS withdrawal is compli-
cated by concurrent nephrectomy which often occurs. There
are no prospective randomised trials of IS withdrawal but
several retrospective studies. Lachmann et al. examined the
sensitisation of 54 adult patients who had failed renal trans-
plants divided into three groups, Group 1 (n = 28, nephrecto-
my and IS withdrawal), group 2 (n = 14, nephrectomy only)
and group 3 (n = 12, IS withdrawal only) [23]. In the first
group, 75% (21 of 28) RTR had undergone nephrectomy in
the first 6 months after transplantation, whereas groups 2 (me-
dian 1919 days post Tx) and 3 (median 3381 days post Tx)
comprised a later vintage and presumably represented a dif-
ferent clinical phenotype. Their results suggested that ne-
phrectomy was associated with a rise in donor specific anti-
HLA class I antibodies, possibly due to the removal of
adsorbing HLA class I antigens in the nephrectomy (Bsponge^
hypothesis). In contrast, the withdrawal of IS was associated
with increasing titres of class II anti-HLA antibodies. Another
important study from the Cambridge group demonstrated the
association of increasing HLA mismatches with donor specif-
ic sensitisation, with each mismatch increasing the chance of
developing donor specific antibodies by 41%, 1 year after
relisting [24]. This finding underpins the importance of
avoiding mismatches in any patient who is likely to require
more than one transplant. They also observed that graft ne-
phrectomy associated with an odds ratio of 3.42 for the devel-
opment of DSAs. Interestingly, remaining on one or two
(usually tacrolimus and MMF) immunosuppressive agents
was associated with an odds ratio of 0.90 and 0.15 respective-
ly for the development of subsequent DSAs. Taken together,
these results suggest that if a second transplant is likely to
occur within 12 months (e.g. live donor or high priority de-
ceased donor renal transplant after early failure) then immu-
nosuppressive therapy should be maintained. This is a com-
plex clinical decision due to the infection risks on dialysis
therapy and should be made according to individual circum-
stances by the transplant team in a timely fashion and docu-
mented before the initiation of renal replacement therapy.
When patients are relisted for a second transplant, then they
will often have a number of unacceptable antigens registered
with NHS Blood and Transplant in the U K. These are based
on the following categories:
& Antigens that correlate with anti-HLA antibodies detected
in serum screening samples that are above a locally agreed
threshold (mean fluorescence intensity –MFI)
& Antibodies that have previously been detected but are no
longer present (historic antibodies)
& Antigens to be avoided since they are present in future
potential live donors
& Antigens that were present on a previous graft that have
never been detected in serum
Local practice varies, and it is essential to establish good
communication with your local Histocompatibility and
Immunogenetics (H&I) Laboratory in order to understand
these processes. Most units in the UK are looking at less
conservative strategies to increase the chances of transplanta-
tion in highly sensitised patients in the first two categories
[25]. Further, scrutiny of the literature suggests that the last
category may be unnecessarily conservative. It has been ar-
gued that any allogenic HLA antigen seen by the immune
system represents Boriginal sin^. Alternatively, it might be
argued that if the relevant antibodies have never been detected
then the recipient immune system is Bregulated^ not to re-
spond. Away from the hypothetical arguments the experimen-
tal data does not support a strong effect. There have been
many retrospective studies looking at repeat mismatches in
second and subsequent transplants but a recent study merits
discussion [26]. The authors looked at 13,789 adult recipients
of second renal transplants carried out in the USA between
1995 and 2011, of which 3868 were had repeated HLA mis-
matches. Repeated mismatches of HLA class I antigens had
no significant effect on any outcomes. Mismatches of HLA
class II antigens had some mild effects particularly in those
who had higher calculated reaction frequency values or who
had undergone graft nephrectomy. This was the largest study
of its kind and was carried out in the era of modern immuno-
suppression and H&I techniques. It is practically important
since removing undetected class I mismatches and in some
Table 1 Advantages and disadvantages of continuing immunosuppression
in renal transplant recipients with failing renal allografts
Advantages Disadvantages
Less sensitisation Malignancy risk
Less rejection Infection risk
Maintain urine output Cardiovascular risk
Avoid nephrectomy Drug side effects
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cases class II mismatches may considerably increase the
chances of a patient receiving a second or subsequent trans-
plant.More importantly, it emphasises the need ofmaintaining
an ongoing dialogue with your H&I Laboratory.
Living donor transplantation has evolved considerably over
the last decade with the establishment of the UK living donor
sharing scheme and the burgeoning of both blood group incom-
patible andHLA-incompatible transplantation. This is important
since some patients who are being evaluated for re-
transplantation may well have been informed that potential do-
nors were unsuitable at the previous time of consideration and it
may worthwhile revisiting the subject of living donation. It is
sensible to check blood group antibody titres (i.e. anti-A1 titres
and anti-B titres in a blood group O recipient) since they can
often be low. Our previous study suggested that approximately a
third of children screened had titres of anti-A or anti-B antibod-
ies that were 1 in 8 or lower [27]. This is a level which would
facilitate relatively low risk ABO incompatible transplantation.
If ABO incompatible deceased donor renal transplantation was
available to children, then this could potentially increase the
transplant activity by 2.2% and reduce the median waiting time
by 21 days. Alternatively, pairs who were previously deemed
incompatible may be considered for the living donor sharing
scheme, and it is notable that this route now contributes more
10% of the overall live donor activity in the UK.
In summary, there is good evidence that the period around
transplant failure is very traumatic for RTRs with a high inci-
dence of physical and psychological illness. There is also a
wide body of evidence to suggest that patient management is
suboptimal at this time with relatively low achievement of
simple targets laid out in guidelines. It is incumbent upon
the transplant community to recognise and treat advanced
CKD effectively in RTR and engage in shared decision mak-
ing to choose options for further renal replacement therapy.
This should include early consideration, education and prep-
aration for a second renal transplant where appropriate.
Self-assessment multiple-choice questions
(answers are provided following the reference
list)
Answer T (true) or F (false) for each:
1. According to United Kingdom Renal Registry data which
of the following attributes is associated with more rapid
progression in failing allografts?
a. Cause of native kidney disease
b. Diabetes mellitus
c. White race
d. Female sex
e. Young age
2. Regarding second and subsequent transplantation
candidates
a. They are more likely to develop cancer
b. Should be weaned of immunosuppression
c. Comprise more than 10% of listed patients in the
United States
d. Mortality rates are approximately 10% in the first year
after graft failure
e. Comprise a higher proportion of the waiting list in
adults than children in the United States
3. The period leading up to allograft loss is associated with
which of the following?
a. Poor blood pressure control
b. Mineral bone disease
c. Higher prevalence of anaemia
d. Metabolic alkalosis
e. A high prevalence of pre-emptive vascular access
placement
4. Which of the following factors are likely to increase sen-
sitisation after failure of a renal transplant?
a. Episodes of late rejection
b. Nephrectomy
c. Blood loss and associated transfusion
d. Extra capsular technique of nephrectomy
e. Maintenance of dual immunosuppression
5. Which of the following is true related to transplant
nephrectomy?
a. Up to 50% of children require graft nephrectomy
b. It is more likely after severe rejection
c. It is more likely after late, as opposed to early, renal
allograft failure
d. Usually results in the removal of all allogeneic material
e. May result in new antibody detection due to loss of
the Bsponge^ effect
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Answers to multiple-choice questions:
1. a. False, b. True, c. False, d. True, e. False; 2. a. True, b. False, c.
True, d. True, e. False; 3. a. True, b. True, c. True, d. False, e. False; 4. a.
True, b. True, c. True, d. False, e. False; 5. a. True, b. True, c. False, d.
False, e. True
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